No Data
US Stock MarketDetailed Quotes
AKBA Akebia Therapeutics
Watchlist
0.9600
-0.0302-3.05% Close 11/28 16:00 ET
0.9601+0.0001+0.01%
Post 18:59 ET
0.9998High0.9515Low558.32KVolume
0.9900Open0.9902Pre Close540.00KTurnover0.33%Turnover RatioLossP/E (TTM)180.85MMarket Cap1.840052wk HighLossP/E (Static)188.39MShares0.280552wk Low-4.59P/B160.65MFloat Cap31.0000Historical High--Dividend TTM167.34MShs Float0.2410Historical Low--Div YieldTTM4.88%Amplitude0.9670Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About Akebia Therapeutics Company
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
Revenue Breakdown
Business
Unit:USD
2022/12/31
Stock NameRevenueRatio
Product revenue, net176.95M60.50%
License, collaboration and other revenue115.54M39.50%
News
Akebia Therapeutics to Present at Piper Sandler Healthcare Conference
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Raises Price Target to $5
HC Wainwright & Co. analyst Ed Arce maintains Akebia Therapeutics (NASDAQ:AKBA) with a Buy and raises the price target from $3.75 to $5.
Akebia Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 11/17/2023 376.19% HC Wainwright & Co. $3.75 → $5 Maintains Buy 09/27/2023 257.14% HC Wainwright & Co. → $
Comments
Update
$Akebia Therapeutics(AKBA.US$ Auryxia (ferric citrate) net product revenue for the third quarter was $40.1 million and management reaffirms previously issued 2023 net product revenue guidance of $170.0 - $175.0 million for Auryxia.
1
$Akebia Therapeutics(AKBA.US$ Hope FDA dont take to long to look at it this time! • The NDA resubmission comes after the FDA in 2022 declined to clear the treatment, which is approved in 35 countries, including Japan, to treat anemia due to CKD in both dialysis-dependent and non-dialysis-dependent adults.
News
$Akebia Therapeutics(AKBA.US$ Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease
3 MINUTES AGO, 8:30 AM EDT
VIA PR NEWSWIRE
3 MINUTES AGO, 8:30 AM EDT
VIA PR NEWSWIRE
1
Read more
Paper Trade
Start
Symbol
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--